David Robert Vincent

Array ( [id] => 16749966 [patent_doc_number] => 20210101975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/125135 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749963 [patent_doc_number] => 20210101972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISORDERS IN PATIENTS WITH ELEVATED LEVELS OF CXCL9 AND OTHER BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/121513 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17121513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511410 [patent_doc_number] => 20230227559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => NEW ANTIBODY BLOCKING HUMAN FCGRIIIA AND FCGRIIIB [patent_app_type] => utility [patent_app_number] => 17/783894 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19135604 [patent_doc_number] => 11970535 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-30 [patent_title] => Treatment with anti-KIR3DL2 agents [patent_app_type] => utility [patent_app_number] => 17/114835 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 36045 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20671944 [patent_doc_number] => 12612444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-28 [patent_title] => T cell receptors targeting mutations in RNA splicing factors [patent_app_type] => utility [patent_app_number] => 17/779711 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 27 [patent_no_of_words] => 8207 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17539874 [patent_doc_number] => 11304978 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy [patent_app_type] => utility [patent_app_number] => 17/100223 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 33 [patent_no_of_words] => 27396 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18065512 [patent_doc_number] => 20220396599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules [patent_app_type] => utility [patent_app_number] => 17/775386 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 302 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16793225 [patent_doc_number] => 20210123042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/098226 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8648 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093188 [patent_doc_number] => 20220411529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => ANTIBODY VARIANT COMBINATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/774333 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42067 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688381 [patent_doc_number] => 20210070857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => IMMUNE CELLS ENGINEERED TO EXPRESS CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/089578 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004967 [patent_doc_number] => 20220363733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ENGINEERED REGULATORY T CELL [patent_app_type] => utility [patent_app_number] => 17/771465 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565689 [patent_doc_number] => 20230256016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => CHIMERIC ANTIGEN RECEPTOR FOR RECOGNIZING FC FRAGMENT AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/795172 [patent_app_country] => US [patent_app_date] => 2020-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17795172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457709 [patent_doc_number] => 12098189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Composition and method for the diagnosis and treatment of iron-related disorders [patent_app_type] => utility [patent_app_number] => 17/034454 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 54907 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622672 [patent_doc_number] => 12590171 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Anti-VHH domain antibodies and use thereof [patent_app_type] => utility [patent_app_number] => 17/753021 [patent_app_country] => US [patent_app_date] => 2020-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 15 [patent_no_of_words] => 13979 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 724 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982607 [patent_doc_number] => 20220348643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => THERAPEUTIC NEUTRALIZATION ANTIBODIES FOR THE TREATMENT OF PEANUT ALLERGY [patent_app_type] => utility [patent_app_number] => 17/762902 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -99 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17762902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16650019 [patent_doc_number] => 10927182 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Humanized BCMA antibody and BCMA-CAR-T cells [patent_app_type] => utility [patent_app_number] => 17/010798 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 3999 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19367403 [patent_doc_number] => 12059464 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer [patent_app_type] => utility [patent_app_number] => 17/008316 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 52 [patent_no_of_words] => 28132 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506212 [patent_doc_number] => 20200385468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/000143 [patent_app_country] => US [patent_app_date] => 2020-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17000143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015394 [patent_doc_number] => 11085021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Compositions and methods for TCR reprogramming using fusion proteins [patent_app_type] => utility [patent_app_number] => 16/989606 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 48 [patent_no_of_words] => 45112 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878009 [patent_doc_number] => 11028142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Compositions and methods for TCR reprogramming using fusion proteins [patent_app_type] => utility [patent_app_number] => 16/989602 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 34 [patent_no_of_words] => 47396 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989602 [rel_patent_id] =>[rel_patent_doc_number] =>)